GlassScriptPhysician profile
Ericka L Petersen
NPI 1073063905
$1,888.80
in general payments reported to CMS, 2019-2025
20 companies · $606 in 2025
The $606 reported for 2025 was more than what 78% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $213 · 2023: $533 · 2024: $537 · 2025: $606.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,576 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,576.18 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $389.56 | 2022-2025 | |
| Lilly USA, LLC | $336.01 | 2023-2025 | Mounjaro, Zepbound, Basaglar |
| Astellas Pharma US INC | $203.18 | 2024-2025 | Veozah |
| E.R. Squibb & Sons, L.L.C. | $183.08 | 2023-2025 | Eliquis, Camzyos |
| Amgen INC. | $145.55 | 2023-2025 | Evenity, Prolia, Prolia |
| Novo Nordisk INC | $117.91 | 2022-2025 | Ozempic, Rybelsus |
| Daiichi Sankyo INC. | $76.44 | 2022-2024 | Injectafer |
| Biohaven Pharmaceutical Holding Company LTD. | $72.14 | 2022 | |
| Glaxosmithkline, LLC. | $68.99 | 2022-2025 | Trelegy Ellipta, Arexvy |
| Exact Sciences Corporation | $47.98 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Janssen Pharmaceuticals, INC | $41.04 | 2022-2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.30 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $32.27 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $29.82 | 2025 | Rexulti |
| Inspire Medical Systems, INC. | $19.52 | 2025 | Inspire |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $19.47 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.46 | 2023 | |
| Abbvie INC. | $18.21 | 2025 | |
| Vertex Pharmaceuticals Incorporated | $17.24 | 2025 | |
| Actelion Pharmaceuticals US, INC. | $13.63 | 2025 | Opsumit, Uptravi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ericka Petersen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.